During its first quarter sales and earnings call on 25 April, AbbVie CEO Robert Michael expressed confidence that the company can weather the current tariffs introduced by the Trump Administration as well as potential upcoming “sectoral tariffs” that could be imposed on the biopharmaceutical industry, but noted AbbVie’s current financial guidance does not account for the possible impact of additional tariffs.
Key Takeaways
- AbbVie CEO Robert Michael said the company is not trying to project the impact of possible future tariffs on imports.
“To the extent there is an impact, we believe it would be in line with our peers given that AbbVie...